{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Azithromycin",
      "COVID-19",
      "SARS-CoV-2",
      "antivirals",
      "cytokine release syndrome",
      "immunomodulation",
      "pneumonia"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "32853038",
  "DateCompleted": {
    "Year": "2021",
    "Month": "02",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "10",
        "Day": "06"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1080/14787210.2020.1813024"
    ],
    "Journal": {
      "ISSN": "1744-8336",
      "JournalIssue": {
        "Volume": "19",
        "Issue": "2",
        "PubDate": {
          "Year": "2021",
          "Month": "Feb"
        }
      },
      "Title": "Expert review of anti-infective therapy",
      "ISOAbbreviation": "Expert Rev Anti Infect Ther"
    },
    "ArticleTitle": "Azithromycin in the treatment of COVID-19: a review.",
    "Pagination": {
      "StartPage": "147",
      "EndPage": "163",
      "MedlinePgn": "147-163"
    },
    "Abstract": {
      "AbstractText": [
        "SARS-CoV-2 is a novel virus that causes coronavirus disease-19 (COVID-19). Antiviral and immunomodulatory agents have been proposed as potential treatments. Azithromycin exhibits both properties and therefore may play a role.",
        "This article reviews the pharmacology, pharmacokinetics, clinical efficacy, and safety of azithromycin in viral infections, with emphasis on COVID-19. A literature search of PUBMED was conducted on May 30<sup>th</sup> and updated on July 28<sup>th</sup>.",
        "Azithromycin presents <i>in vitro</i> activity against SARS-CoV-2 and could act in different points of the viral cycle. Its immunomodulatory properties include the ability to downregulate cytokine production, maintain epithelial cell integrity or prevent lung fibrosis. Azithromycin use was associated with a reduction in mortality and ventilation days in other viral infections. These properties could be beneficial throughout the COVID-19. However, the evidence of its use is scarce and of low quality. Azithromycin has been assessed in retrospective observational studies mainly in combination with hydroxychloroquine, which has shown to provide no benefit. This macrolide presents a well-known safety profile. Upcoming clinical trials will determine the role of azithromycin in the COVID-19 (including the stage of the disease where it offers the greatest benefits and the effect of its combination with other drugs)."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0003-4975-8798"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service of Pharmacy, Hospital Del Mar, Hospital Del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital Del Mar d'Investigacions M\u00e8diques (IMIM) , Barcelona, Spain."
          }
        ],
        "LastName": "Echeverr\u00eda-Esnal",
        "ForeName": "Daniel",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service of Pneumology, Hospital Del Mar , Barcelona, Spain."
          }
        ],
        "LastName": "Martin-Ontiyuelo",
        "ForeName": "Clara",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service of Pharmacy, Hospital Del Mar, Hospital Del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital Del Mar d'Investigacions M\u00e8diques (IMIM) , Barcelona, Spain."
          }
        ],
        "LastName": "Navarrete-Rouco",
        "ForeName": "Mar\u00eda Eugenia",
        "Initials": "ME"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service of Pharmacy, Hospital Del Mar, Hospital Del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital Del Mar d'Investigacions M\u00e8diques (IMIM) , Barcelona, Spain."
          }
        ],
        "LastName": "De-Antonio Cusc\u00f3",
        "ForeName": "Marta",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service of Pharmacy, Hospital Del Mar, Hospital Del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital Del Mar d'Investigacions M\u00e8diques (IMIM) , Barcelona, Spain."
          }
        ],
        "LastName": "Ferr\u00e1ndez",
        "ForeName": "Olivia",
        "Initials": "O"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service of Infectious Diseases, Hospital Del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital Del Mar d'Investigacions M\u00e8diques (IMIM) , Spain."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Pharmacy, Universitat Aut\u00f2noma De Barcelona , Barcelona, Spain."
          }
        ],
        "LastName": "Horcajada",
        "ForeName": "Juan Pablo",
        "Initials": "JP"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service of Pharmacy, Hospital Del Mar, Hospital Del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital Del Mar d'Investigacions M\u00e8diques (IMIM) , Barcelona, Spain."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Pharmacy, Universitat Aut\u00f2noma De Barcelona , Barcelona, Spain."
          }
        ],
        "LastName": "Grau",
        "ForeName": "Santiago",
        "Initials": "S"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Expert Rev Anti Infect Ther",
    "NlmUniqueID": "101181284",
    "ISSNLinking": "1478-7210"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunologic Factors"
    },
    {
      "RegistryNumber": "83905-01-5",
      "NameOfSubstance": "Azithromycin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Azithromycin"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Immunologic Factors"
    },
    {
      "QualifierName": [
        "drug effects",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ]
}